Canada
To supplement routine materials and enhance overall risk-benefit balance discussions, Educational Programme Materials have been developed for PrBYOOVIZTM. The content of these materials has been assessed by Health Canada in line with their Marketing Authorisation requirements.
Byooviz (ranibizumab)